Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPPING: maintenance pazopanib versus placebo after first-line chemotherapy in non-progressive NSCLC
NL-OMON37952Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pazopanib maintenance with Placebo maintenance (2 arms). Primary endpoint: Overall survival. Started Aug 2011; status: recruiting.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON37952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37952.